Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Vital Therapies Secures $16 Million for Trial of Artificial Liver Device

publication date: Oct 3, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Vital Therapies, a San Diego company that is developing a device to treat liver failure, has closed a $16 million capital round from its existing investors, the first of a planned $76 million multi-stage commitment. Last year, Vital Therapies raised $2 million from Jilin Aodong Medicine and was slated to receive an additional $25 million in six months if Vital Therapies was successful in obtaining SFDA approval of its device. The approval was not secured. More details....

Stock Symbol: (SHE: 000623)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors